68Ga-FAP-2286 PET在实体瘤中的应用:生物分布、剂量学及与18F-FDG的比较
本研究对46例实体瘤患者行68Ga-FAP-2286 PET显像,评估其生物分布与剂量学,并与18F-FDG PET及既往FAPI化合物比较。结果显示肉瘤、胆管癌和结肠癌摄取最高,肺癌和睾丸癌最低;在胆管癌、乳腺癌、结肠癌、肝细胞癌、头颈癌和胰腺腺癌中,68Ga-FAP-2286 PET的SUVmax均显著高于18F-FDG PET。全身有效剂量估计为1.16E-02 mSv/MBq,膀胱壁吸收剂量最高(9.98E-02 mGy/MBq)。
要点
- 68Ga-FAP-2286 PET在肉瘤、胆管癌和结肠癌中摄取最高,肺癌和睾丸癌最低。
- 在胆管癌、乳腺癌、结肠癌、肝细胞癌、头颈癌和胰腺腺癌中,68Ga-FAP-2286 PET的SUVmax显著高于18F-FDG PET。
- 全身有效剂量估计为1.16E-02 mSv/MBq,膀胱壁吸收剂量最高为9.98E-02 mGy/MBq。
核心结论
- 68Ga-FAP-2286的生物分布、剂量学和肿瘤摄取与既往报道的FAPI化合物相似。
- 68Ga-FAP-2286 PET的摄取 consistently 高于18F-FDG PET。
- 这些结果在小体积病变和区分肿瘤与炎性摄取方面尤其有前景。
研究设计与样本
- 患者接受219 ± 43 MBq的68Ga-FAP-2286后60分钟进行PET扫描。
- 每例患者最多测量5个病灶以及肾脏、脾脏、肝脏和纵隔(血池)的摄取。
- 吸收剂量使用MIM Encore和OLINDA/EXM版本1.1评估,采用国际放射防护委员会第103号出版物的组织权重因子。
- 共46例患者接受了68Ga-FAP-2286 PET显像。
主要发现
- 平均摄取最高的肿瘤为肉瘤、胆管癌和结肠癌,最低的为肺癌和睾丸癌。
- 胆管癌中68Ga-FAP-2286 PET的平均SUVmax为18.2 ± 6.4,18F-FDG PET为9.1 ± 5.0(P = 0.007)。
- 乳腺癌中68Ga-FAP-2286 PET的平均SUVmax为11.1 ± 6.8,18F-FDG PET为4.1 ± 2.2(P < 0.001)。
- 结肠癌中68Ga-FAP-2286 PET的平均SUVmax为13.8 ± 2.2,18F-FDG PET为7.6 ± 1.7(P = 0.001)。
- 肝细胞癌中68Ga-FAP-2286 PET的平均SUVmax为9.3 ± 3.5,18F-FDG PET为4.7 ± 1.3(P = 0.01);头颈癌中分别为11.3 ± 3.5 vs. 7.6 ± 5.5(P = 0.04);胰腺腺癌中分别为7.4 ± 1.8 vs. 3.7 ± 1.0(P = 0.01)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein (FAP), expressed in the tumor microenvironment of a variety of cancers, has become a target of novel PET tracers. The purpose of this report is to evaluate the imaging characteristics of 68Ga-FAP-2286, present the first-to our knowledge-dosimetry analysis to date, and compare the agent with 18F-FDG and FAPI compounds. Methods: Patients were administered 219 ± 43 MBq of 68Ga-FAP-2286 and scanned after 60 min. Uptake was measured in up to 5 lesions per patient and within the kidneys, spleen, liver, and mediastinum (blood pool). Absorbed doses were evaluated using MIM Encore and OLINDA/EXM version 1.1 using the International Commission on Radiological Protection publication 103 tissue weighting factor. Results: Forty-six patients were imaged with 68Ga-FAP-2286 PET. The highest average uptake was seen in sarcoma, cholangiocarcinoma, and colon cancer. The lowest uptake was found in lung cancer and testicular cancer. The average SUVmax was significantly higher on 68Ga-FAP-2286 PET than on 18F-FDG PET in cholangiocarcinoma (18.2 ± 6.4 vs. 9.1 ± 5.0, P = 0.007), breast cancer (11.1 ± 6.8 vs. 4.1 ± 2.2, P < 0.001), colon cancer (13.8 ± 2.2 vs. 7.6 ± 1.7, P = 0.001), hepatocellular carcinoma (9.3 ± 3.5 vs. 4.7 ± 1.3, P = 0.01), head and neck cancer (11.3 ± 3.5 vs. 7.6 ± 5.5, P = 0.04), and pancreatic adenocarcinoma (7.4 ± 1.8 vs. 3.7 ± 1.0, P = 0.01). The total-body effective dose was estimated at 1.16E-02 mSv/MBq, with the greatest absorbed organ dose in the urinary bladder wall (9.98E-02 mGy/MBq). Conclusion: 68Ga-FAP-2286 biodistribution, dosimetry, and tumor uptake were similar to those of previously reported FAPI compounds. Additionally,68Ga-FAP-2286 PET had consistently higher uptake than 18F-FDG PET. These results are especially promising in the setting of small-volume disease and differentiating tumor from inflammatory uptake.
引用
- Kline B, Yadav S, Seo Y, et al. 68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG. J Nucl Med. 2024. PMID: 38697672. doi:10.2967/jnumed.123.267281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。